Vitreoretinal Diseases: Current Treatment and Future Advances
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Ophthalmology".
Deadline for manuscript submissions: 20 March 2025 | Viewed by 102
Special Issue Editors
Interests: age-related macular degeneration; diabetic eye disease; early-stage diabetic retinopathy; epidemiology of vitreoretinal diseases in developing countries; functional testings; intermediate AMD; myopia; objective perimetry; targeted therapy
Interests: visual disease; age-related macular degeneration; diabetic eye disease; early-stage diabetic retinopathy; epidemiology of vitreoretinal diseases in developing countries; functional testings; intermediate AMD; myopia; objective perimetry; targeted therapy
Special Issue Information
Dear Colleagues,
We all know there are various treatment modalities for vitreoretinal (VR) diseases. Some are very effective like anti-VEGF treatment, which was once regarded as a wonder drug or one-day drug due to its efficacy at treating conditions such as diabetic macular oedema (DMO). Diabetic retinopathy (DR), DMO, and neovascular age-related macular degeneration (nAMD) are common major vascular diseases that cause retinal blindness or visual impairment. Currently, we have treatments for both—laser therapy and anti-VEGF injection for DR and anti-VEGF and laser procedures for the nAMD. But, these treatment modalities are not without complications and side effects. In DR, pan-retinal photocoagulation causes night blindness and constricts visual fields, and stopping anti-VEGF therapy can result in rapid worsening of DR. In nAMD, anti-VEGF treatment has resulted in a new challenge—the emergence of post-treatment geographic atrophy (GA). Similarly, treatment of other VR diseases results in complications and side effects.
The only possible approach to avoid iatrogenic complications is to find better management through therapeutic, laser, or surgical advances.
Therefore, through this Special Issue of JCM, we will firstly collect and highlight the current treatment of VR diseases and, secondly, discuss potential future targeted therapies with no or minimal side effects or complications, including publications on clinical trials and stem cell and gene-based therapies.
Dr. Bhim Bahadur Rai
Prof. Dr. Ted Maddess
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- age-related macular degeneration
- chorioretinopathy
- diabetic retinopathy
- diagnostics targeting early stage diseases
- therapeutics targeting early stage diseases
- macular hole
- retinal diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
